Owlstone Medical's strategic collaboration with Actelion Pharmaceuticals Ltd., one of The Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and validate a breath-based test to aid early diagnosis of pulmonary hypertension, has been featured in an article by BioWorld MedTech.
Actelion partners with Owlstone Medical to Bring Breath Biopsy to Pulmonary Hypertension
Here are two exerpts from the article:
J&J acquired Actelion in a $30 billion deal that closed in June 2017. Its position in pulmonary arterial hypertension (PAH) treatments was one of the driving forces behind the massive deal. It has at least five PAH treatments that cover a spectrum of the disease, including oral, inhaled and intravenous medications.
Last spring, Owlstone launched Breath Biopsy research kits for use to identify breath biomarkers. These are being used in the context of its pharma partnerships.
Click here to read the full article on BioWorld MedTech:
If you want to learn more about how Owlstone Medical's Breath Sampling and Analysis technology and Services are being utilized in early detection and precision medicine, why not download our free ebook: Breath Biopsy: The Complete Guide?